EGFR and urinary bladder cancer: Significantly enhanced cytotoxicity and tumor growth inhibition up to complete tumor resorption, prolonged tumor retention of radioactivity, along with possible clinical translation of the pharmacokinetic profile of 111In attached to EGFR-targeted MNT on a human bladder cancer animal model observed in this study warrants further steps toward the development of this approach.